Synopsis:
– The corporate reported rise of 830% in Web Revenue on Q-o-Q foundation at Rs 23.29 crore
– Firm’s income for Q1FY26 is Rs 299.91 crores
– Firm not too long ago accomplished seven export-sourcing assignments totalling Rs 299.91 crores
– Firm had earlier secured a serious Rs 517 crore international sourcing mandate from Thailand-based Fortune Sagar Impex Firm Restricted
Welcure Medication & Prescribed drugs Ltd, right now introduced its monetary outcomes for the quarter ended June 30, 2025 (Q1FY26). The corporate has reported a sturdy monetary efficiency within the first quarter of FY26, pushed by its strategic foray into fee-based, export-oriented sourcing providers.
Welcure’s income from operations rose sharply to Rs 299.91 crores in Q1FY26, up from Rs 21.21 crores earlier quarter Q4FY25, making it about 1300% rise on Q-o-Q foundation. The corporate reported Web Revenue of Rs 23.29 crores in Q1FY26 as towards a internet lack of Rs 0.34 crores in the identical interval final yr Q1FY25. The corporate reported virtually 830% rise in Web Revenue on Q-o-Q foundation when in comparison with Web Revenue of Rs 2.5 crore registered in Q4FY25 that ended on March 31, 2025. Earnings per share (EPS) stood at Rs 2.07 in Q1FY26 as in comparison with Rs -0.26 in Q1FY25.
Talking on the stellar monetary efficiency of Q1FY26, the administration of the corporate commented, “The robust monetary efficiency in Q1FY26, is a mirrored image of our enterprise methods, meticulous selections and our centered transition to a fee-based, asset-light mannequin. We’re dedicated to sustaining this efficiency by environment friendly provide chain administration and product diversification.”
The corporate has not too long ago accomplished seven export-sourcing assignments totalling Rs 299.91 crores, performing solely as a procurement agent on behalf of worldwide patrons. The corporate earns a hard and fast 5% fee on these transactions, with no publicity to stock, logistics, or working capital dangers, preserving its debt-free construction. This shift towards fee-based export providers has considerably enhanced Welcure’s income profile, with fee revenue acknowledged in accordance with Ind AS 115 on receipt foundation.
Moreover, Welcure had earlier secured a serious Rs 517 crore international sourcing mandate from Thailand-based Fortune Sagar Impex Firm Restricted, anticipated to contribute an estimated Rs 25.85 crores in service revenue throughout FY26.
The corporate carried out necessary management selections to streamline governance for sturdy progress. The corporate appointed Mr Rabi Thakor as an Extra Non-Govt Non-Impartial Director. The corporate additionally appointed Mr. Yogeshkumar Prajapati and Mrs. Bhumika Pradhan joined as Extra Impartial Administrators.
Integrated in 1992, Welcure Medication & Prescribed drugs Ltd is a longtime pharmaceutical firm in India, engaged within the manufacture and commerce of a variety of healthcare formulations. With a concentrate on high quality, compliance, and international integration, Welcure continues to broaden its presence in each home and worldwide markets.
Disclaimer
The views and funding suggestions expressed by funding consultants/broking homes/ranking companies on tradebrains.in are their very own, and never that of the web site or its administration. Investing in equities poses a threat of economic losses. Traders should due to this fact train due warning whereas investing or buying and selling in shares. Commerce Brains Applied sciences Personal Restricted or the writer usually are not answerable for any losses triggered because of the choice primarily based on this text. Please seek the advice of your funding advisor earlier than investing.
